INVENTIVA ADS/1 O.N.
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. The company develops Lanifibranor, a novel pan-peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat … Read more
Market Cap & Net Worth: INVENTIVA ADS/1 O.N. (6IVA)
INVENTIVA ADS/1 O.N. (F:6IVA) has a market capitalization of $1.00 Billion (€978.82 Million) as of March 18, 2026. Listed on the F stock exchange, this Germany-based company holds position #9980 globally and #1067 in its home market, demonstrating a -1.92% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying INVENTIVA ADS/1 O.N.'s stock price €5.10 by its total outstanding shares 191925703 (191.93 Million).
INVENTIVA ADS/1 O.N. Market Cap History: 2020 to 2026
INVENTIVA ADS/1 O.N.'s market capitalization history from 2020 to 2026. Data shows change from $2.05 Billion to $1.00 Billion (-10.09% CAGR).
INVENTIVA ADS/1 O.N. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how INVENTIVA ADS/1 O.N.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 6IVA by Market Capitalization
Companies near INVENTIVA ADS/1 O.N. in the global market cap rankings as of March 18, 2026.
Key companies related to INVENTIVA ADS/1 O.N. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
INVENTIVA ADS/1 O.N. Historical Marketcap From 2020 to 2026
Between 2020 and today, INVENTIVA ADS/1 O.N.'s market cap moved from $2.05 Billion to $ 1.00 Billion, with a yearly change of -10.09%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €1.00 Billion | +58.39% |
| 2025 | €634.36 Million | +63.45% |
| 2024 | €388.10 Million | -46.47% |
| 2023 | €724.98 Million | -14.42% |
| 2022 | €847.13 Million | -62.61% |
| 2021 | €2.27 Billion | +10.58% |
| 2020 | €2.05 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of INVENTIVA ADS/1 O.N. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.00 Billion USD |
| MoneyControl | $1.00 Billion USD |
| MarketWatch | $1.00 Billion USD |
| marketcap.company | $1.00 Billion USD |
| Reuters | $1.00 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.